摘要
Alzheimer disease (AD) is the most common neurodegenerative disease. Unfortunately, current effective therapeutics for AD are limited and thus the discovery of novel anti-AD agents is urgently needed. A key pathological hallmark of AD is the accumulation of phosphorylated MAPT/tau (microtubule associated protein tau) aggregates to form neurofibrillary tangles. Autophagy is a conserved catabolic process that degrades protein aggregates or organelles via lysosomes. TFEB (transcription factor EB), a master regulator of autophagy, transcriptionally regulates multiple autophagy, and lysosomal-related genes. A compromised autophagy-lysosomal pathway (ALP) has been implicated in AD progression, and enhancing TFEB-mediated ALP to degrade MAPT/tau aggregates is a promising anti-AD strategy. In a recent study, we showed that celastrol, a natural small molecule with an anti-obesity effect, is a novel TFEB activator, which enhances autophagy and lysosomal biogenesis both in vitro and in animal brains. Consequently, celastrol promotes the degradation of phosphorylated MAPT/tau aggregates both in cells and in the brain of P301S MAPT/tau and 3XTg mice, two commonly used AD animal models. Interestingly, celastrol also alleviates memory deficits in these mice. Altogether, celastrol enhances TFEB-mediated autophagy and lysosomal biogenesis to ameliorate MAPT/tau pathology, suggesting that celastrol represents a novel anti-AD and other tauopathies drug candidate.
学科与关键词
- Impairment of the autophagy-lysosomal pathway in Alzheimer's diseases: Pathogenic mechanisms and therapeutic potentialZhang, Wei; Xu, Chengchao; Sun, Jichao; Shen, Han-Ming*; Wang, Jigang*; Yang, Chuanbin*Acta Pharmaceutica Sinica B, 2022, 12(3): 1019-1040.被引 49
- Clemastine attenuates AD-like pathology in an AD model mouse via enhancing mTOR-mediated autophagyLi, Zhen-Yu; Chen, Li-Hua; Zhao, Xiu-Yun; Chen, Hong; Sun, Yan-Yun; Lu, Mei-Hong; Wang, Zhao-Tao; Chen, Mei; Lu, Li; Huang, Wenhui; Chen, Rui; Xu, De-En*; Xu, Ru-Xiang*; Ma, Quan-Hong*Experimental Neurology, 2021, 342: 113742.被引 17
- TNEA therapy promotes the autophagic degradation of NLRP3 inflammasome in a transgenic mouse model of Alzheimer's disease via TFEB/TFE3 activationLin, Wenjia; Li, Zhao; Liang, Guangfeng; Zhou, Runjin; Zheng, Xiaoyan; Tao, Rongrong; Huo, Qingwei; Su, Chengfu; Li, Min; Xu, Nenggui*; Tang, Chunzhi*; Song, Ju-Xian*Journal of Neuroinflammation, 2023, 20(1): 21.被引 2
